Prevention of Harmful Drug Reactions in Pharmacovigilance System

doi:10.19803/j.1672-8629.2021.01.10

Abstract

Abstract: The pharmacovigilance system is the most basic system for drug safety risk management throughout the life cycle of drugs,involving the detection,identification,assessment and prevention of harmful drug reactions.Among the four tasks,prevention,which is the most advanced element of the pharmacovigilance system compared with the adverse drug reaction monitoring system,is overlapping with the other three,which is why the research on prevention should be strengthened.By interpreting the concept of pharmacovigilance systems in China ,analyzing China's practices and summarizing foreign experience on prevention of harmful drug reactions,this paper proposes that we can strengthen the prevention of harmful drug reactions by enhancing the awareness of risk prevention in the early stage of drug research and development,making registration review and approval rigorous,attaching importance to the monitoring of adverse reactions in individual cases,formulating relief systems for drug misadventures,promoting the safety of medicine use,and encouraging exploratory research.

Key words: pharmacovigilance system, harmful drug reactions, adverse drug reaction, prevention

CLC Number:

R951

SONG Yingjie, WANG Haiyan, LI Yujia. Prevention of Harmful Drug Reactions in Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 52-55.

References

[1] Shi L,liu X,Zhang B.Study on recognition of drug toxicity in pharmacovigilance thought of the compendium of materia medica[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(6):347-351.
[2] Guo PJ,Zhang B,Lin ZJ,et al.Analysis of pharmacovigilance thoughts in herbal masterpieces of Ming Dynasty[J].Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志),2020,26(5):186-191.
[3] Zhang XM,Xu MD,Chen WG.Research on national sentinel alliance for adverse drug reaction surveillance based on CHPS[J].Chinese Pharmaceutical Affairs(中国药事),2019,33(2):137-142.
[4] Cong LL,Bai YX,Li HY,et al.Comparison of pharmacovigilance information utilization in WHO,Europe,USA and China[J].Chinese Journal of New Drugs(中国新药杂志),2015,24(8):845-848,874.
[5] Yang Y.Implementation of pharmacovigilance system in drug administration law and application of ICH E2 Guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(2):65-71.
[6] Wang LL,Yang Y,Wang SL.Application of the US FDA sentinel system and enlightenment[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(2):81-87.
[7] Stang P E,Ryan P B,Racoosin JA,et al.Advancing the science for active surveillance:Rationale and design for the observational medical outcomes partnership[J].Annals of Internal Medicine,2010,153(9):600-606.
[8] Zhang GJ,Chu XY,Tian YJ,et al.Implication of EU parmacovigilance system to China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2015,12(10):593-595,596.
[9] Arlett P,Strauss &Rasi G.Pharmacovigilance 2030[J].Clinical Pharmacology and Therapeutics,2020,107(1):89-91.
[10] Xu L,Zhao YJ,Li F,et al.Brief introduction and its implication on the drug risk management system in Japan[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志),2010,26(10):784-789.
[11] Zhong LM.MAHs’Principal responsibilities for safety risk during the whole-life cycle of drugs[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(11):666-669,677.
[12] Yuan L,Shao ML.US FDA new drug expedited review strategies and its implications for China[J].Chinese Journal of New Drugs(中国新药杂志),2015,24(21):2401-2404,2409.
[13] National Medical Products Administration.Annual report for national adverse drug reaction monitoring (2019)[EB/OL].(2020-04-13)[2020-07-02].http://www.nmpa.gov.cn/WS04/CL2155/376451.html.
[14] Shu L.Analysis of common people's drug use behavior-report from "Survey of Safe Use of Drugs by common people"[J].Chinese Consumer Magazine(中国消费者杂志),2005(7):19-20.
[15] Stone NJ,Robinson G,LichtensteinAH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Journal of the American College of Cardiology,2014,63(25):2889-2934.
[16] Cai RY.Analysis of whether Chinese ACS patients can tolerate high-intensity statin therapy according to clinical cases[J].Strait Pharmaceutical Journal(海峡药学),2018,30(9):240-243.